Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 190

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study

Open access
Froyman, Wouter, Landolfo, Chiara, De Cock, Bavo, Wynants, Laure, Sladkevicius, Povilas, Testa, Antonia Carla, Van Holsbeke, Caroline, Domali, Ekaterini, Fruscio, Robert, Epstein, Elisabeth, dos Santos Bernardo, Maria José, Franchi, Dorella, Kudla, Marek Jerzy, Chiappa, Valentina, Alcazar, Juan Luis, Leone, Francesco Paolo Giuseppe, Buonomo, Francesca, Hochberg, Lauri, Coccia, Maria Elisabetta, Guerriero, Stefano, Deo, Nandita, Jokubkiene, Ligita, Kaijser, Jeroen, Coosemans, An, Vergote, Ignace, Verbakel, Jan Yvan, Bourne, Tom, Van Calster, Ben, Valentin, Lil, Timmerman, Dirk · 2019 · The Lancet Oncology

Abstract

BACKGROUND Ovarian tumours are usually surgically removed because of the presumed risk of complications. Few large prospective studies on long-term follow-up of adnexal masses exist. We aimed to estimate the cumulative incidence of cyst complications and malignancy during the first 2 years of follow-up after adnexal masses have been classified as benign by use of ultrasonography. METHODS In the international, prospective, cohort International Ovarian Tumor Analysis Phase 5 (IOTA5) study, patients aged 18 years or older with at least one adnexal mass who had been selected for surgery or conservative management after ultrasound assessment were recruited consecutively from 36 cancer and non-cancer centres in 14 countries. Follow-up of patients managed conservatively is ongoing at present. In this 2-year interim analysis, we analysed patients who were selected for conservative management of an adnexal mass judged to be benign on ultrasound on the basis of subjective assessment of ultrasound images. Conservative management included ultrasound and clinical follow-up at intervals of 3 months and 6 months, and then every 12 months thereafter. The main outcomes of this 2-year interim analysis were cumulative incidence of spontaneous resolution of the mass, torsion or cyst rupture, or borderline or invasive malignancy confirmed surgically in patients with a newly diagnosed adnexal mass. IOTA5 is registered with ClinicalTrials.gov, number NCT01698632, and the central Ethics Committee and the Belgian Federal Agency for Medicines and Health Products, number S51375/B32220095331, and is ongoing. FINDINGS Between Jan 1, 2012, and March 1, 2015, 8519 patients were recruited to IOTA5. 3144 (37%) patients selected for conservative management were eligible for inclusion in our analysis, of whom 221 (7%) had no follow-up data and 336 (11%) were operated on before a planned follow-up scan was done. Of 2587 (82%) patients with follow-up data, 668 (26%) had a mass that was already in follow-up at recruitment, and 1919 (74%) presented with a new mass at recruitment (ie, not already in follow-up in the centre before recruitment). Median follow-up of patients with new masses was 27 months (IQR 14-38). The cumulative incidence of spontaneous resolution within 2 years of follow-up among those with a new mass at recruitment (n=1919) was 20·2% (95% CI 18·4-22·1), and of finding invasive malignancy at surgery was 0·4% (95% CI 0·1-0·6), 0·3% (<0·1-0·5) for a borderline tumour, 0·4% (0·1-0·7) for torsion, and 0·2% (<0·1-0·4) for cyst rupture. INTERPRETATION Our results suggest that the risk of malignancy and acute complications is low if adnexal masses with benign ultrasound morphology are managed conservatively, which could be of value when counselling patients, and supports conservative management of adnexal masses classified as benign by use of ultrasound. FUNDING Research Foundation Flanders, KU Leuven, Swedish Research Council.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(18)30837-4

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 190

Metadata

Authors
Froyman, W., Landolfo, C., De Cock, B., Wynants, L., Sladkevicius, P., Testa, A. C., Van Holsbeke, C., Domali, E., Fruscio, R., Epstein, E., dos Santos Bernardo, M. J., Franchi, D., Kudla, M. J., Chiappa, V., Alcazar, J. L., Leone, F. P. G., Buonomo, F., Hochberg, L., Coccia, M. E., Guerriero, S., Deo, N., Jokubkiene, L., Kaijser, J., Coosemans, A., Vergote, I., Verbakel, J. Y., Bourne, T., Van Calster, B., Valentin, L., & Timmerman, D.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2019-03
Volume
20
Issue
3
Pages
448-458
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2913847982
Cited by
190
References
3
FWCI
16.32
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study. https://app.cochat.ai/papers/10.1016/s1470-2045(18)30837-4
The paper
Froyman, W., Landolfo, C., De Cock, B., Wynants, L., Sladkevicius, P., Testa, A. C., Van Holsbeke, C., Domali, E., Fruscio, R., Epstein, E., dos Santos Bernardo, M. J., Franchi, D., Kudla, M. J., Chiappa, V., Alcazar, J. L., Leone, F. P. G., Buonomo, F., Hochberg, L., Coccia, M. E., . . . Timmerman, D. (2019). Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(18)30837-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.